Strategic Pathways in Cell and Gene Therapy

Strategic Pathways in Cell and Gene Therapy

Drawing upon deep industry expertise, this edition offers a rigorous examination of the Cell and Gene Therapy (CGT) landscape. Navigating contemporary manufacturing shifts, we probe the momentum of personalized cancer therapies and provide an evidence-based perspective on the nuances of rare tumor indications.


Is CGT Manufacturing Poised for a Paradigm Shift?

As the demand for innovative treatments escalates, CGT manufacturing stands at a pivotal juncture. We spotlight strategic implications of decentralized manufacturing, automation, and Single-use Technologies (SUTs). Our analysis reveal how CGT decision-makers are addressing manufacturing challenges to ensure consistent, high-quality therapeutic production...read here


Cell and Gene Therapy (CGT) – Revolutionizing Personalized Cancer Treatment

Cancer remains one of the most formidable challenges in healthcare. However, the dawn of adoptive cellular therapy offers a beacon of hope. With over 5,380 clinical trials anticipated by 2030, the oncology cell therapy landscape is poised for significant transformation. As we venture deeper into this realm, the potential of CGT in revolutionizing cancer treatment becomes increasingly evident...explore more


Are Decentralization and Automation the Keys for Crafting Tomorrow's CGT?

In the biopharmaceutical landscape, cell and gene therapies (CGT) are redefining manufacturing. Amid challenges like delivery and contamination, innovations like disposable production technology emerge, potentially cutting costs by 30%. Industry leaders are leveraging single-use technology, pointing to a transformative future for CGT manufacturing. Explore more in our webinar...watch it here


Rare Tumors on the Brink of a Therapeutic Revolution

The quest for effective treatments for rare tumors is intensifying. Our research highlights a roadmap for potential opportunities, therapy modalities, and unmet needs. Dive into the multifaceted world of rare tumors and explore strategic pathways that can lead to transformative solutions in healthcare...read here


Join the conversation with industry experts and be a part of bold trends in the world of innovative technologies

Our Upcoming Webinars

  1. Current and Future Trends: Cell Therapies in Oncology

Date: November 3, 2023

Time: 10.30 AM CET | 4.30 PM CET | 2.30 PM EST

Register Here >>


2. Scope 1,2,3 Emission Reduction in Steel Industry

Date: November 8, 2023

Time: 10.30 AM CET | 4.30 PM CET | 2.30 PM EST

Register Here >>


3. Evaluating Landscape of Incontinence Management Solutions

Date: November 9, 2023

Time: 10.30 AM CET | 4.30 PM CET | 2.30 PM EST

Register Here >>


About FutureBridge

FutureBridge is a techno-commercial consulting and advisory company.?We track and advise on the future of industries from a 1-to-25-year perspective to?keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and facilitate best-fit solutions and partnerships using our platforms, programs, and access to global ecosystems and players.?

Contact Us?|?Follow us on?LinkedIn?and?Twitter

Dana Robert Colarulli

Executive Director, @LESI & Partner @ ACG | JD, IP Policy Expert and Government Relations Specialist

1 年

FutureBridge does solid analysis for the industry’s that LES members care about and have been a great partner in supporting our Automotive Indutry advisory board and other constituencies. Worth paying attention to! Licensing Executives Society International (LESI)

要查看或添加评论,请登录

FutureBridge的更多文章

社区洞察

其他会员也浏览了